ASH 2024 Updates —AURIGA: Daratumumab Plus Lenalidomide in Maintenance Post Transplant
Panelists discuss how the AURIGA trial demonstrates superior outcomes with daratumumab plus lenalidomide maintenance compared with lenalidomide alone after autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma while examining key subgroup analyses that inform treatment decisions regarding posttransplant maintenance therapy selection.
EP: 1.Expert Insights: Evolving Treatment Landscape in NDMM
EP: 2.Key Highlights From the PERSEUS and CASSIOPEIA Studies
EP: 3.ASH 2024 Updates —AURIGA: Daratumumab Plus Lenalidomide in Maintenance Post Transplant
EP: 4.Anti-CD38 Quadruplet Induction Regimens in TE NDMM: New Standard of Care
EP: 5.Clinical Perspectives: Selecting Between Daratumumab- and Isatuximab-Containing Quadruplet Induction Regimens
EP: 6.ASH 2024 Highlights: GMMG-HD7 Study
EP: 7.Where Are We Going? Future Perspectives on Navigating the Treatment Paradigm in Transplant-Eligible NDMM
EP: 8.Key Highlights: CEPHEUS Trial SubQ Dara-VRd vs VRd in Transplant-Eligible or Transplant-Deferred NDMM
EP: 9.Transplant-Ineligible NDMM: When to Use a Quadruplet Regimen
EP: 10.Expert Perspectives: Navigating Between CEPHEUS and IMROZ Studies
EP: 11.Challenges in Treating Frail Patients With NDMM: In the Real-World Practice: Potential Steroid-Free Regimens
EP: 12.Future Perspectives: What’s Next in NDMM?
EP: 13.Assessing CD38 Monoclonal Antibody-Based Regimens in NDMM
Video content above is prompted by the following:
- For patients who have received ASCT, please comment on the latest data from the AURIGA trial, evaluating daratumumab plus lenalidomide maintenance in NDMM.
- AURIGA trial, subgroup analysis
- How does the data impact your choice of subsequent treatment, post induction therapy?
![We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fa0c5316b5733cfe8ccceb396476faf0cea2f2e46-320x410.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
